Premium
Intravitreal dexamethasone implant in the treatment of postoperative cystoid macular edema (Irvine Gass syndrom): one year retrospective study
Author(s) -
LANDRé C,
GASTAUD P,
BAILLIF S
Publication year - 2014
Publication title -
acta ophthalmologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.534
H-Index - 87
eISSN - 1755-3768
pISSN - 1755-375X
DOI - 10.1111/j.1755-3768.2014.f094.x
Subject(s) - medicine , macular edema , dexamethasone , visual acuity , ophthalmology , intraocular pressure , implant , retrospective cohort study , surgery
Purpose To evaluate the efficacy of dexamethasone 0.7mg intravitreal implant in patients with chronic postoperative cystoid macular edema. Methods Fourteen patients’ charts were retrospectively reviewed. Inclusion criteria comprised patients with postoperative cystoid macular edema. The main outcome measures were best corrected visual acuity (BCVA) and mean central retinal thickness (CRT). Results Patients mean age was 72.1 years. All patients were pseudophakic. Six patients were diabetic. Four patients had received a previous treatment with intravitreal ranimizumab. The mean BCVA before intravitreal dexamethasone was 0.75 logmar. It improved to 0.56 at month 1 and was 0,45 at month 3. The pre injection mean CRT was 584.6 µm. It improved to 309 µm at month 1 and was 341,5 at month 3. Seven patients presented an elevated intraocular pressure during the follow up Conclusion Intravitreal dexamethasone implant improved visual acuity and macular thickness at month 1 and month 3 in patients with postoperative cystoid macular edema. However its beneficial effect seemed to decrease at month 3.